All Stories

  1. Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective

    Article • ClinicoEconomics and Outcomes Research, November 2018, Dove Medical Press

    Cory Gamble

  2. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States

    Article • Journal of Medical Economics, July 2017, Taylor & Francis

    Cory Gamble, Barnaby Hunt